Literature DB >> 14645571

Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Alexandra Trkola1, Herbert Kuster, Christine Leemann, Claudia Ruprecht, Beda Joos, Amalio Telenti, Bernhard Hirschel, Rainer Weber, Sebastian Bonhoeffer, Huldrych F Günthard.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) isolates from 20 chronically infected patients who participated in a structured treatment interruption (STI) trial were studied to determine whether viral fitness influences reestablishment of viremia. Viruses derived from individuals who spontaneously controlled viremia had significantly lower in vitro replication capacities than viruses derived from individuals that did not control viremia after interruption of antiretroviral therapy (ART), and replication capacities correlated with pre-ART and post-STI viral set points. Of note, no clinically relevant improvement of viral loads upon STI occurred. Virus isolates from controlling and noncontrolling patients were indistinguishable in terms of coreceptor usage, genetic subtype, and sensitivity to neutralizing antibodies. In contrast, viruses from controlling patients exhibited increased sensitivity to inhibition by chemokines. Sensitivity to inhibition by RANTES correlated strongly with slower replication kinetics of the virus isolates, suggesting a marked dependency of these virus isolates on high coreceptor densities on the target cells. In summary, our data indicate that viral fitness is a driving factor in determining the magnitude of viral rebound and viral set point in chronic HIV-1 infection, and thus fitness should be considered as a parameter influencing the outcome of therapeutic intervention in chronic infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645571      PMCID: PMC296087          DOI: 10.1128/jvi.77.24.13146-13155.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Individualising HIV treatment--pharmacogenetics and immunogenetics.

Authors:  Amalio Telenti; Vincent Aubert; François Spertini
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

2.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

3.  Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.

Authors:  Annette Oxenius; David A Price; Sara J Dawson; Huldrych F Günthard; Marek Fischer; Luc Perrin; Elbe Ramirez; Catherine Fagard; Bernard Hirschel; George Scullard; Jonathan N Weber; Angela R McLean; Rodney E Phillips
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

4.  Procedures for reliable estimation of viral fitness from time-series data.

Authors:  Sebastian Bonhoeffer; Andrew D Barbour; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2002-09-22       Impact factor: 5.349

5.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP).

Authors:  M Bunce; C M O'Neill; M C Barnardo; P Krausa; M J Browning; P J Morris; K I Welsh
Journal:  Tissue Antigens       Date:  1995-11

6.  Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.

Authors:  Javier Martinez-Picado; Kristina Morales-Lopetegi; Terri Wrin; Julia G Prado; Simon D W Frost; Christos J Petropoulos; Bonaventura Clotet; Lidia Ruiz
Journal:  AIDS       Date:  2002-04-12       Impact factor: 4.177

7.  RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.

Authors:  W A Paxton; A U Neumann; S Kang; L Deutch; R C Brown; R A Koup; S M Wolinsky
Journal:  J Infect Dis       Date:  2001-04-25       Impact factor: 5.226

8.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.

Authors:  G Scarlatti; T Leitner; V Hodara; M Jansson; A Karlsson; J Wahlberg; P Rossi; M Uhlén; E M Fenyö; J Albert
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  24 in total

1.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

5.  Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions.

Authors:  Yegor Voronin; Julie Overbaugh; Michael Emerman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Authors:  Peter Rusert; Herbert Kuster; Beda Joos; Benjamin Misselwitz; Cornelia Gujer; Christine Leemann; Marek Fischer; Gabriela Stiegler; Hermann Katinger; William C Olson; Rainer Weber; Leonardo Aceto; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit.

Authors:  Chu Wang; Donglai Liu; Tao Zuo; Bhavna Hora; Fangping Cai; Haitao Ding; John Kappes; Christina Ochsenbauer; Wei Kong; Xianghui Yu; Tanmoy Bhattacharya; Alan S Perelson; Feng Gao
Journal:  J Infect       Date:  2019-12-05       Impact factor: 6.072

8.  HIV-1 coreceptor switch during 2 years of structured treatment interruptions.

Authors:  S Baroncelli; C M Galluzzo; M Andreotti; M F Pirillo; V Fragola; L E Weimer; M Giuliano; S Vella; L Palmisano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

9.  R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.

Authors:  Silvana Tasca; Siu-Hong Ho; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection.

Authors:  Angela Ciuffi; Gabriela Bleiber; Miguel Muñoz; Raquel Martinez; Corinne Loeuillet; Manuela Rehr; Marek Fischer; Huldrych F Günthard; Annette Oxenius; Pascal Meylan; Sebastian Bonhoeffer; Didier Trono; Amalio Telenti
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.